TET2 and acute lymphoblastic leukemia: As with most molecular lesions in T-ALL, loss of TET2 did not associate with molecular subtype, prognosis, or key clinical parameters in a well-characterized cohort of 262 pediatric T-ALL patients (SI Appendix, Fig. S1F) (32).